Cognitive Pharmaceuticals, LTD

Toledo, OH 43604

SBIR Award Summary

Total Number of Awards 6
Total Value of Awards $1.8MM
First Award Date 05/01/02
Most Recent Award Date 09/21/07

Key Personnel

Last Name Name Awards Contact
Ghosh Debasis Ghosh 1
Mcguire Edward J Mcguire 5

6 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-27
Budget: 09/21/07 - 07/31/08

DESCRIPTION (provided by applicant): The overall goal of the proposed research is to develop selective muscarinic agonists for the treatment of psychosis and cognitive dysfunction associated with schizophrenia. Cognitive deficits, including impaired memory function, are strongly linked to the long- term disabilities found in patients with schizo...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/05 - 06/30/07

DESCRIPTION (provided by applicant): The purpose of this Phase II SBIR proposal is to continue the development of CDD-0102 as a potential treatment for Alzheimer's disease (AD). Accomplishments from the Phase I award included demonstration of the stimulation of alpha-secretase by CDD-0102, identification of the major metabolizing enzymes and the...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-27
Budget: 05/01/05 - 04/30/07

DESCRIPTION (provided by applicant): The purpose of the proposed project is to develop a new muscarinic agonist for the treatment of schizophrenia. Compounds that activate M1 and M4 muscarinic receptors are expected to be particularly useful in treating memory and cognitive deficits, as well as the behavioral disturbances associated with schizop...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/15/04 - 06/30/05

DESCRIPTION (provided by applicant): The purpose of this Phase II SBIR proposal is to continue the development of CDD-0102 as a potential treatment for Alzheimer's disease (AD). Accomplishments from the Phase I award included demonstration of the stimulation of alpha-secretase by CDD-0102, identification of the major metabolizing enzymes and the...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-27
Budget: 05/01/04 - 04/30/05

DESCRIPTION (provided by applicant): The purpose of the proposed project is to develop a new muscarinic agonist for the treatment of schizophrenia. Compounds that activate M1 and M4 muscarinic receptors are expected to be particularly useful in treating memory and cognitive deficits, as well as the behavioral disturbances associated with schizop...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/02 - 10/31/03

DESCRIPTION (provided by applicant): The purpose of the present study is to assess the utility of muscarinic agonists in treating Alzheimer's disease. Levels of acetylcholine decrease in Alzheimer's disease, resulting in memory deficits. Efforts to treat Alzheimer's disease have been based on compounds that mimic acetylcholine without producing ...